Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping

被引:18
作者
Maurice, Carleta B. [1 ]
Barua, Pankaj K. [1 ]
Simses, Diane [1 ]
Smith, Penny [2 ]
Howe, John G. [2 ]
Stack, Gary [1 ,2 ]
机构
[1] VA Connecticut Healthcare Syst, Pathol & Lab Med Serv, West Haven, CT 06516 USA
[2] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA
关键词
Warfarin; CYP2C9; VKORC1; Genotyping assays; COMMERCIAL PLATFORMS; AFRICAN-AMERICANS; POLYMORPHISMS; REQUIREMENTS; PERFORMANCE; PREDICT; IMPACT;
D O I
10.1016/j.cca.2010.03.005
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background. A variety of commercial genotyping assays is available to detect variants in the CYP2C9 and VKORC1 genes. The assay results are used in genotype-based warfann dosing algorithms We compared the performance of four such assay systems: Vengene (R), eSensor (R), Invader (R), and Luminex (R). Methods Result concordance and no call rates were determined on patient specimens tested on all four instruments. Turnaround times (TAT), hands-on time (HOT), pipetting steps and cost were obtained for runs of 1, 8 and 24 samples Results. The four assays were 100% concordant for the common CYP2C9 and VKORC1 alleles (n= 100). Vengene had the shortest TAT and HOT for 1 and 8 samples. Vengene had the fewest wetting steps for all sample sizes, while Invader had the most. Luminex had the longest TAT and highest cost for all sample run sizes. Vengene had the lowest cost for 1 and 8 samples and Invader the lowest for 24 samples The no call rates for Vengene. Luminex. eSensor. and Invader were 10%, 4%. 1% and 0%. respectively. Conclusions All assays gave comparable results for common variants Each system offered unique advantages and disadvantages, whose relative importance depends on the needs of the adopting clinical laboratory Published by Elsevier B.V.
引用
收藏
页码:947 / 954
页数:8
相关论文
共 35 条
[1]   Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations [J].
Allabi, AC ;
Gala, JL ;
Desager, JP ;
Heusterspreute, M ;
Horsmans, Y .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) :653-657
[2]   Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [J].
Anderson, Jeffrey L. ;
Horne, Benjamin D. ;
Stevens, Scott M. ;
Grove, Amanda S. ;
Barton, Stephanie ;
Nicholas, Zachery P. ;
Kahn, Samera F. S. ;
May, Heidi T. ;
Samuelson, Kent M. ;
Muhlestein, Joseph B. ;
Carlquist, John F. .
CIRCULATION, 2007, 116 (22) :2563-2570
[3]   Managing oral anticoagulant therapy [J].
Ansell, J ;
Hirsh, J ;
Dalen, J ;
Bussey, H ;
Anderson, D ;
Poller, L ;
Jacobson, A ;
Deykin, D ;
Matchar, D .
CHEST, 2001, 119 (01) :22S-38S
[4]   Comparison of performance of three commercial platforms for warfarin sensitivity genotyping [J].
Babic, Nikolina ;
Haverfield, Eden V. ;
Burrus, Julie A. ;
Lozada, Anthony ;
Das, Soma ;
Yeo, Kiang-Teck J. .
CLINICA CHIMICA ACTA, 2009, 406 (1-2) :143-147
[5]   Discovery of new potentially defective alleles of human CYP2C9 [J].
Blaisdell, J ;
Jorge-Nebert, LF ;
Coulter, S ;
Ferguson, SS ;
Lee, SJ ;
Chanas, B ;
Xi, T ;
Mohrenweiser, H ;
Ghanayem, B ;
Goldstein, JA .
PHARMACOGENETICS, 2004, 14 (08) :527-537
[6]   Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity [J].
Bodin, L ;
Verstuyft, C ;
Tregouet, DA ;
Robert, A ;
Dubert, L ;
Funck-Brentano, C ;
Jaillon, P ;
Beaune, P ;
Laurent-Puig, P ;
Becquemont, L ;
Loriot, MA .
BLOOD, 2005, 106 (01) :135-140
[7]  
BUTZ KG, 2007, JMD, V9, P653
[8]   CYP4F2 genetic variant alters required warfarin dose [J].
Caldwell, Michael D. ;
Awad, Tarif ;
Johnson, Julie A. ;
Gage, Brian F. ;
Falkowski, Mat ;
Gardina, Paul ;
Hubbard, Jason ;
Turpaz, Yaron ;
Langaee, Taimour Y. ;
Eby, Charles ;
King, Cristi R. ;
Brower, Amy ;
Schmelzer, John R. ;
Glurich, Ingrid ;
Vidaillet, Humberto J. ;
Yale, Steven H. ;
Zhang, Kai Qi ;
Berg, Richard L. ;
Burmester, James K. .
BLOOD, 2008, 111 (08) :4106-4112
[9]   Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans [J].
Dickmann, LJ ;
Rettie, AE ;
Kneller, MB ;
Kim, RB ;
Wood, AJJ ;
Stein, CM ;
Wilkinson, GR ;
Schwarz, UI .
MOLECULAR PHARMACOLOGY, 2001, 60 (02) :382-387
[10]   Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation [J].
Eckman, Mark H. ;
Rosand, Jonathan ;
Greenberg, Steven M. ;
Gage, Brian F. .
ANNALS OF INTERNAL MEDICINE, 2009, 150 (02) :73-U31